Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

CD8+ T cells mediate ultraviolet A-induced immunomodulation in a model of extracorporeal photochemotherapy.

Hequet O, Nosbaum A, Guironnet-Paquet A, Blasco E, Nicolas-Virelizier E, Griffith TS, Rigal D, Cognasse F, Nicolas JF, Vocanson M.

Eur J Immunol. 2020 Feb 3. doi: 10.1002/eji.201948318. [Epub ahead of print]

PMID:
32012249
2.

A wild microbiome improves mouse modeling of the human immune response.

Hamilton SE, Griffith TS.

Lab Anim (NY). 2019 Nov;48(11):337-338. doi: 10.1038/s41684-019-0421-8. No abstract available.

PMID:
31591550
3.

Microbial Exposure Enhances Immunity to Pathogens Recognized by TLR2 but Increases Susceptibility to Cytokine Storm through TLR4 Sensitization.

Huggins MA, Sjaastad FV, Pierson M, Kucaba TA, Swanson W, Staley C, Weingarden AR, Jensen IJ, Danahy DB, Badovinac VP, Jameson SC, Vezys V, Masopust D, Khoruts A, Griffith TS, Hamilton SE.

Cell Rep. 2019 Aug 13;28(7):1729-1743.e5. doi: 10.1016/j.celrep.2019.07.028.

4.

Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.

Danahy DB, Kurup SP, Winborn CS, Jensen IJ, Harty JT, Griffith TS, Badovinac VP.

J Immunol. 2019 Aug 1;203(3):725-735. doi: 10.4049/jimmunol.1900435. Epub 2019 Jun 12.

PMID:
31189573
5.

Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses.

Picarda G, Ghosh R, McDonald B, Verma S, Thiault N, El Morabiti R, Griffith TS, Benedict CA.

J Virol. 2019 Jul 30;93(16). pii: e00617-19. doi: 10.1128/JVI.00617-19. Print 2019 Aug 15.

6.

Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival.

Danahy DB, Jensen IJ, Griffith TS, Badovinac VP.

J Immunol. 2019 May 15;202(10):2843-2848. doi: 10.4049/jimmunol.1900076. Epub 2019 Apr 10.

PMID:
30971442
7.

Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.

Kim H, Khanna V, Kucaba TA, Zhang W, Ferguson DM, Griffith TS, Panyam J.

Mol Pharm. 2019 Mar 4;16(3):1200-1210. doi: 10.1021/acs.molpharmaceut.8b01165. Epub 2019 Jan 25.

PMID:
30620878
8.

Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.

Kim H, Griffith TS, Panyam J.

J Pharmacol Exp Ther. 2019 Sep;370(3):715-724. doi: 10.1124/jpet.118.254953. Epub 2019 Jan 4. Review.

PMID:
30610006
9.

Polymicrobial Sepsis Chronic Immunoparalysis Is Defined by Diminished Ag-Specific T Cell-Dependent B Cell Responses.

Sjaastad FV, Condotta SA, Kotov JA, Pape KA, Dail C, Danahy DB, Kucaba TA, Tygrett LT, Murphy KA, Cabrera-Perez J, Waldschmidt TJ, Badovinac VP, Griffith TS.

Front Immunol. 2018 Oct 31;9:2532. doi: 10.3389/fimmu.2018.02532. eCollection 2018.

10.

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM.

Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12.

11.

Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.

Kim H, Sehgal D, Kucaba TA, Ferguson DM, Griffith TS, Panyam J.

Nanoscale. 2018 Nov 15;10(44):20851-20862. doi: 10.1039/c8nr07201a.

PMID:
30403212
12.

Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections.

Jensen IJ, Winborn CS, Fosdick MG, Shao P, Tremblay MM, Shan Q, Tripathy SK, Snyder CM, Xue HH, Griffith TS, Houtman JC, Badovinac VP.

PLoS Pathog. 2018 Oct 31;14(10):e1007405. doi: 10.1371/journal.ppat.1007405. eCollection 2018 Oct.

13.

Cutting Edge: Elevated Leptin during Diet-Induced Obesity Reduces the Efficacy of Tumor Immunotherapy.

Murphy KA, James BR, Sjaastad FV, Kucaba TA, Kim H, Brincks EL, Chua SC Jr, Wilber A, Griffith TS.

J Immunol. 2018 Oct 1;201(7):1837-1841. doi: 10.4049/jimmunol.1701738. Epub 2018 Aug 22.

14.

Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.

Petersburg JR, Shen J, Csizmar CM, Murphy KA, Spanier J, Gabrielse K, Griffith TS, Fife B, Wagner CR.

ACS Nano. 2018 Jul 24;12(7):6563-6576. doi: 10.1021/acsnano.8b01308. Epub 2018 Jun 4.

15.

HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes.

Tasyurek HM, Eksi YE, Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S.

Gene Ther. 2018 Jul;25(4):269-283. doi: 10.1038/s41434-018-0011-1. Epub 2018 Mar 9.

PMID:
29523882
16.

Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.

Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS, Panyam J.

Biomaterials. 2018 May;164:38-53. doi: 10.1016/j.biomaterials.2018.02.034. Epub 2018 Feb 17.

PMID:
29482062
17.

Sepsis-Induced T Cell Immunoparalysis: The Ins and Outs of Impaired T Cell Immunity.

Jensen IJ, Sjaastad FV, Griffith TS, Badovinac VP.

J Immunol. 2018 Mar 1;200(5):1543-1553. doi: 10.4049/jimmunol.1701618. Review.

18.

Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes.

Tasyurek HM, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S.

Hum Gene Ther. 2018 Jul;29(7):802-815. doi: 10.1089/hum.2017.180. Epub 2018 Mar 20.

PMID:
29409356
19.

The current status of immunobased therapies for metastatic renal-cell carcinoma.

Sathianathen NJ, Krishna S, Anderson JK, Weight CJ, Gupta S, Konety BR, Griffith TS.

Immunotargets Ther. 2017 Dec 5;6:83-93. doi: 10.2147/ITT.S134850. eCollection 2017. Review.

20.

Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.

Larson P, Kucaba TA, Xiong Z, Olin M, Griffith TS, Ferguson DM.

ACS Med Chem Lett. 2017 Oct 16;8(11):1148-1152. doi: 10.1021/acsmedchemlett.7b00256. eCollection 2017 Nov 9.

21.

TRAIL Deletion Prevents Liver, but Not Adipose Tissue, Inflammation during Murine Diet-Induced Obesity.

Hirsova P, Weng P, Salim W, Bronk SF, Griffith TS, Ibrahim SH, Gores GJ.

Hepatol Commun. 2017 Sep;1(7):648-662. doi: 10.1002/hep4.1069. Epub 2017 Jul 20.

22.

The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.

Sathianathen NJ, Krishna S, Konety BR, Griffith TS.

Immunotherapy. 2017 Sep;9(12):1005-1018. doi: 10.2217/imt-2017-0051.

PMID:
28971750
23.

Polymicrobial sepsis impairs bystander recruitment of effector cells to infected skin despite optimal sensing and alarming function of skin resident memory CD8 T cells.

Danahy DB, Anthony SM, Jensen IJ, Hartwig SM, Shan Q, Xue HH, Harty JT, Griffith TS, Badovinac VP.

PLoS Pathog. 2017 Sep 14;13(9):e1006569. doi: 10.1371/journal.ppat.1006569. eCollection 2017 Sep.

24.

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies.

Murphy KA, James BR, Wilber A, Griffith TS.

J Vis Exp. 2017 Apr 12;(122). doi: 10.3791/55080.

25.

Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice.

Guicciardi ME, Krishnan A, Bronk SF, Hirsova P, Griffith TS, Gores GJ.

Cell Death Dis. 2017 Jan 5;8(1):e2535. doi: 10.1038/cddis.2016.459.

26.

Polymicrobial Sepsis Diminishes Dendritic Cell Numbers and Function Directly Contributing to Impaired Primary CD8 T Cell Responses In Vivo.

Strother RK, Danahy DB, Kotov DI, Kucaba TA, Zacharias ZR, Griffith TS, Legge KL, Badovinac VP.

J Immunol. 2016 Dec 1;197(11):4301-4311. Epub 2016 Oct 26.

27.

Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of disease.

Cabrera-Perez J, Badovinac VP, Griffith TS.

Exp Biol Med (Maywood). 2017 Jan;242(2):127-139. doi: 10.1177/1535370216669610. Epub 2016 Oct 4. Review.

28.

Clinical and Experimental Sepsis Impairs CD8 T-Cell-Mediated Immunity.

Danahy DB, Strother RK, Badovinac VP, Griffith TS.

Crit Rev Immunol. 2016;36(1):57-74. doi: 10.1615/CritRevImmunol.2016017098. Review.

29.

CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas.

Murphy KA, Griffith TS.

Cancers (Basel). 2016 Jul 27;8(8). pii: E71. doi: 10.3390/cancers8080071. Review.

30.

Gut Microbial Membership Modulates CD4 T Cell Reconstitution and Function after Sepsis.

Cabrera-Perez J, Babcock JC, Dileepan T, Murphy KA, Kucaba TA, Badovinac VP, Griffith TS.

J Immunol. 2016 Sep 1;197(5):1692-8. doi: 10.4049/jimmunol.1600940. Epub 2016 Jul 22.

31.

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms.

Di Bartolo BA, Cartland SP, Prado-Lourenco L, Griffith TS, Gentile C, Ravindran J, Azahri NS, Thai T, Yeung AW, Thomas SR, Kavurma MM.

J Am Heart Assoc. 2015 Nov 16;4(11). pii: e002527. doi: 10.1161/JAHA.115.002527.

32.

Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Brincks EL, Kucaba TA, James BR, Murphy KA, Schwertfeger KL, Sangwan V, Banerjee S, Saluja AK, Griffith TS.

FEBS J. 2015 Dec;282(24):4747-4765. doi: 10.1111/febs.13532. Epub 2015 Oct 18.

33.

Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

Amarante-Mendes GP, Griffith TS.

Pharmacol Ther. 2015 Nov;155:117-31. doi: 10.1016/j.pharmthera.2015.09.001. Epub 2015 Sep 5. Review.

34.

Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Murphy KA, James BR, Guan Y, Torry DS, Wilber A, Griffith TS.

Hum Vaccin Immunother. 2015;11(7):1612-20. doi: 10.1080/21645515.2015.1035849.

35.

Polymicrobial Sepsis Increases Susceptibility to Chronic Viral Infection and Exacerbates CD8+ T Cell Exhaustion.

Condotta SA, Khan SH, Rai D, Griffith TS, Badovinac VP.

J Immunol. 2015 Jul 1;195(1):116-25. doi: 10.4049/jimmunol.1402473. Epub 2015 May 15.

36.

The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Laudenbach M, Baruffaldi F, Vervacke JS, Distefano MD, Titcombe PJ, Mueller DL, Tubo NJ, Griffith TS, Pravetoni M.

J Immunol. 2015 Jun 15;194(12):5926-36. doi: 10.4049/jimmunol.1500385. Epub 2015 May 13.

37.

Alterations in antigen-specific naive CD4 T cell precursors after sepsis impairs their responsiveness to pathogen challenge.

Cabrera-Perez J, Condotta SA, James BR, Kashem SW, Brincks EL, Rai D, Kucaba TA, Badovinac VP, Griffith TS.

J Immunol. 2015 Feb 15;194(4):1609-20. doi: 10.4049/jimmunol.1401711. Epub 2015 Jan 16.

38.

Immunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell function.

Markwart R, Condotta SA, Requardt RP, Borken F, Schubert K, Weigel C, Bauer M, Griffith TS, Förster M, Brunkhorst FM, Badovinac VP, Rubio I.

PLoS One. 2014 Dec 26;9(12):e115094. doi: 10.1371/journal.pone.0115094. eCollection 2014.

39.

CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.

James BR, Anderson KG, Brincks EL, Kucaba TA, Norian LA, Masopust D, Griffith TS.

Cancer Immunol Immunother. 2014 Nov;63(11):1213-27. doi: 10.1007/s00262-014-1598-8. Epub 2014 Aug 21.

40.

Impact of sepsis on CD4 T cell immunity.

Cabrera-Perez J, Condotta SA, Badovinac VP, Griffith TS.

J Leukoc Biol. 2014 Nov;96(5):767-77. doi: 10.1189/jlb.5MR0114-067R. Epub 2014 May 2. Review.

41.

Minimal changes in the systemic immune response after nephrectomy of localized renal masses.

Wald G, Barnes KT, Bing MT, Kresowik TP, Tomanek-Chalkley A, Kucaba TA, Griffith TS, Brown JA, Norian LA.

Urol Oncol. 2014 Jul;32(5):589-600. doi: 10.1016/j.urolonc.2014.01.023. Epub 2014 Apr 24.

42.

Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells.

James BR, Brincks EL, Kucaba TA, Boon L, Griffith TS.

Cancer Immunol Immunother. 2014 Jul;63(7):685-97. doi: 10.1007/s00262-014-1548-5. Epub 2014 Apr 8.

43.

GLP-1-mediated gene therapy approaches for diabetes treatment.

Tasyurek MH, Altunbas HA, Canatan H, Griffith TS, Sanlioglu S.

Expert Rev Mol Med. 2014 Mar 26;16:e7. doi: 10.1017/erm.2014.7. Review.

PMID:
24666581
44.

Polymicrobial sepsis alters antigen-dependent and -independent memory CD8 T cell functions.

Duong S, Condotta SA, Rai D, Martin MD, Griffith TS, Badovinac VP.

J Immunol. 2014 Apr 15;192(8):3618-25. doi: 10.4049/jimmunol.1303460. Epub 2014 Mar 19.

45.

Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival.

Rodrigue-Gervais IG, Labbé K, Dagenais M, Dupaul-Chicoine J, Champagne C, Morizot A, Skeldon A, Brincks EL, Vidal SM, Griffith TS, Saleh M.

Cell Host Microbe. 2014 Jan 15;15(1):23-35. doi: 10.1016/j.chom.2013.12.003.

46.

Intravascular staining for discrimination of vascular and tissue leukocytes.

Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, Qunaj L, Griffith TS, Vezys V, Barber DL, Masopust D.

Nat Protoc. 2014 Jan;9(1):209-22. doi: 10.1038/nprot.2014.005. Epub 2014 Jan 2.

47.

Clinical utility of insulin and insulin analogs.

Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S.

Islets. 2013 Mar-Apr;5(2):67-78. doi: 10.4161/isl.24590. Epub 2013 Mar 1.

48.

T-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppression.

Condotta SA, Cabrera-Perez J, Badovinac VP, Griffith TS.

Crit Rev Immunol. 2013;33(1):23-40. Review.

49.

PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.

Brincks EL, Risk MC, Griffith TS.

Semin Cancer Biol. 2013 Jun;23(3):183-9. doi: 10.1016/j.semcancer.2013.02.002. Epub 2013 Feb 11. Review.

PMID:
23410637
50.

Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection.

Condotta SA, Rai D, James BR, Griffith TS, Badovinac VP.

J Immunol. 2013 Mar 1;190(5):1991-2000. doi: 10.4049/jimmunol.1202379. Epub 2013 Jan 25.

Supplemental Content

Loading ...
Support Center